| Replacement Information | |
|---|---|
| Replacement Information | 05-516 is a recommended replacement for CBL751 |
Special Offers
100% Performance Guaranteed
Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H, R, M | ELISA, FC, ICC, IHC, IP, WB | M | Purified | Monoclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | 05-516 |
| Replaces | CBL751 |
| Brand Family | Upstate |
| Trade Name |
|
| Description | Anti-Ras Antibody, clone RAS10 |
| Alternate Names |
|
| Background Information | The tumor oncoproteins HRas, KRas, and NRas are rated as Ras protoncogenes. Point mutations within Ras genes are frequently detected in human malignancies and in experimentally induced tumors in animals. |
| Product Information | |
|---|---|
| Format | Purified |
| Control |
|
| Presentation | Purified mouse monoclonal IgG2ak in buffer containing PBS, pH 7.4, with 0.05% sodium azide and 30% glycerol. Liquid at -20°C. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Detect Ras using this Anti-Ras Antibody, clone RAS10 validated for use in ELISA, FC, IC, IH, IP & WB. |
| Key Applications |
|
| Application Notes | Immunoprecipitation: 1-4 μg of this antibody has been reported to immunoprecipitate Ras. Immunocytochemistry: 2.5 μg/mL of this antibody has been reported to show positive immunostaining for Ras in SW480 and Y1 cells. Immunohistochemistry: This antibody has been reported to detect Ras in frozen and paraffin embedded breast carcinoma sections. |
| Biological Information | |
|---|---|
| Immunogen | Purified recombinant Ras. Clone RAS10. |
| Clone | RAS10 |
| Concentration | Please refer to the Certificate of Analysis for the lot-specific concentration. |
| Host | Mouse |
| Specificity | This antibody recognizes p21H-, K- and N-Ras. |
| Isotype | IgG2aκ |
| Species Reactivity |
|
| Species Reactivity Note | Proven to react with human, mouse and rat. Other species unknown. |
| Antibody Type | Monoclonal Antibody |
| Entrez Gene Number |
|
| Entrez Gene Summary | Members of the RAS superfamily of GTP-binding proteins, which includes MRAS, are membrane-anchored, intracellular signal transducers responsible for a variety of normal cellular functions. They are oncogenically activated in a significant fraction of tumors.[supplied by OMIM] |
| Gene Symbol |
|
| Purification Method | Protein G Purified |
| UniProt Number |
|
| UniProt Summary | FUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Enzyme regulation:Alternate between an inactive form bound to GDP and an active form bound to GTP. Activated by a guanine nucleotide-exchange factor (GEF) and inactivated by a GTPase-activating protein (GAP). SIZE: 189 amino acids; 21,656 Da SUBUNIT: Interacts with PHLPP (By similarity). SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor; Cytoplasmic side. Involvement in disease: Defects in KRAS are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. Defects in KRAS are a cause of juvenile myelomonocytic leukemia (JMML) [MIM:607785]. JMML is a pediatric myelodysplastic syndrome that constitutes approximately 30% of childhood cases of myelodysplastic syndrome (MDS) and 2% of leukemia. It is characterized by leukocytosis with tissue infiltration and in vitro hypersensitivity of myeloid progenitors to granulocyte-macrophage colony stimulating factor. Defects in KRAS are the cause of Noonan syndrome 3 (NS3) [MIM:609942]. Noonan syndrome (NS) [MIM:163950] is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis. It is a genetically heterogeneous and relatively common syndrome, with an estimated incidence of 1 in 1000-2500 live births. Rarely, NS is associated with juvenile myelomonocytic leukemia (JMML). NS3 inheritance is autosomal dominant. Defects in KRAS are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant. KRAS mutations are involved in cancer development. |
| Molecular Weight | 21 kDa |
| Product Usage Statements | |
|---|---|
| Quality Assurance | Routinely evaluated by western blot on RIPA lysate from human A431 carcinoma cells, human HFF, Jurkat, Raji, mouse 3T3, CTLL, rat L-6 or PC-12 cell lysates. Western Blot Analysis: 0.05 - 0.5 μg/mL of this lot detected Ras in RIPA lysate from human A431 carcinoma cells. A previous lot detected Ras in human HFF, Jurkat, Raji, mouse 3T3, CTLL, rat L-6 and PC- 12 cell lysates. |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Stable for 1 year at -20ºC from date of receipt. |
| Packaging Information | |
|---|---|
| Material Size | 100 µg |